DelveInsight’s “Pulmonary Sarcoidosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Pulmonary Sarcoidosis, historical and forecasted epidemiology as well as the Pulmonary Sarcoidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pulmonary Sarcoidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pulmonary Sarcoidosis Market Forecast
Some of the key facts of the Pulmonary Sarcoidosis Market Report:
- The Pulmonary Sarcoidosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- While the majority of patients with pulmonary sarcoidosis recover, increased mortality was observed in those who were older, had extensive fibrosis on high resolution computer tomography, or had pulmonary hypertension (PH), according to a study titled "Predictors of mortality in pulmonary sarcoidosis" carried out by Kirkil, G. et al. (2018)
- Efzofitimod's Phase 1b/2a Clinical Study for the Treatment of Pulmonary Sarcoidosis Positive Results Published by aTyr Pharma in the Journal CHEST
- Key Pulmonary Sarcoidosis Companies: aTyr Pharma, Inc., Kinevant Sciences GmbH, Novartis, Mallinckrodt, Gilead Sciences, Centocor, Inc., Actelion, Eilly Lilly, United Therapeutics, Reata Pharmaceuticals, Inc., and others
- Key Pulmonary Sarcoidosis Therapies: ATYR1923, Namilumab, CMK389, Efzofitimod 3 mg, CMK389, Namilumab, ACZ885, Acthar Gel, Ambrisentan, Infliximab, Selexipag, Tadalafil, Inhaled Treprostinil:, Bardoxolone methyl, and others
- The Pulmonary Sarcoidosis epidemiology based on gender analyzed that Pulmonary Sarcoidosis is more common in women than in men
- The Pulmonary Sarcoidosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Sarcoidosis pipeline products will significantly revolutionize the Pulmonary Sarcoidosis market dynamics.
Pulmonary Sarcoidosis Overview
Granulomas, or microscopic clusters of inflammatory cells, develop in one or more body organs as a result of the inflammatory disease sarcoidosis. Chronic inflammation can cause fibrosis, which is the irreversible scarring of organ tissue, if it is not controlled. Pulmonary sarcoidosis is the name for sarcoidosis of the lungs. In most cases, the granulomas heal and disappear on their own.
Get a Free sample for the Pulmonary Sarcoidosis Market Report
https://www.delveinsight.com/report-store/pulmonary-sarcoidosis-market
Pulmonary Sarcoidosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Pulmonary Sarcoidosis Epidemiology Segmentation:
The Pulmonary Sarcoidosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Pulmonary Sarcoidosis
- Prevalent Cases of Pulmonary Sarcoidosis by severity
- Gender-specific Prevalence of Pulmonary Sarcoidosis
- Diagnosed Cases of Episodic and Chronic Pulmonary Sarcoidosis
Download the report to understand which factors are driving Pulmonary Sarcoidosis epidemiology trends @ Pulmonary Sarcoidosis Epidemiology Forecast
Pulmonary Sarcoidosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Sarcoidosis market or expected to get launched during the study period. The analysis covers Pulmonary Sarcoidosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pulmonary Sarcoidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Pulmonary Sarcoidosis Therapies and Key Companies
- ATYR1923: aTyr Pharma, Inc.
- Namilumab: Kinevant Sciences GmbH
- CMK389: Novartis
- Efzofitimod 3 mg: aTyr Pharma, Inc.
- CMK389: Novartis Pharmaceuticals
- Namilumab: Kinevant Sciences GmbH
- ACZ885: Novartis Pharmaceuticals
- Acthar Gel: Mallinckrodt
- Ambrisentan: Gilead Sciences
- Infliximab: Centocor, Inc.
- Selexipag: Actelion
- Tadalafil: Eilly Lilly
- Inhaled Treprostinil: United Therapeutics
- Bardoxolone methyl: Reata Pharmaceuticals, Inc.
Discover more about therapies set to grab major Pulmonary Sarcoidosis market share @ Pulmonary Sarcoidosis Treatment Market
Scope of the Pulmonary Sarcoidosis Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Pulmonary Sarcoidosis Companies: aTyr Pharma, Inc., Kinevant Sciences GmbH, Novartis, Mallinckrodt, Gilead Sciences, Centocor, Inc., Actelion, Eilly Lilly, United Therapeutics, Reata Pharmaceuticals, Inc., and others
- Key Pulmonary Sarcoidosis Therapies: ATYR1923, Namilumab, CMK389, Efzofitimod 3 mg, CMK389, Namilumab, ACZ885, Acthar Gel, Ambrisentan, Infliximab, Selexipag, Tadalafil, Inhaled Treprostinil:, Bardoxolone methyl, and others
- Pulmonary Sarcoidosis Therapeutic Assessment: Pulmonary Sarcoidosis current marketed and Pulmonary Sarcoidosis emerging therapies
- Pulmonary Sarcoidosis Market Dynamics: Pulmonary Sarcoidosis market drivers and Pulmonary Sarcoidosis market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Pulmonary Sarcoidosis Unmet Needs, KOL’s views, Analyst’s views, Pulmonary Sarcoidosis Market Access and Reimbursement
To know more about Pulmonary Sarcoidosis companies working in the treatment market, visit @ Pulmonary Sarcoidosis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Pulmonary Sarcoidosis Market Report Introduction
2. Executive Summary for Pulmonary Sarcoidosis
3. SWOT analysis of Pulmonary Sarcoidosis
4. Pulmonary Sarcoidosis Patient Share (%) Overview at a Glance
5. Pulmonary Sarcoidosis Market Overview at a Glance
6. Pulmonary Sarcoidosis Disease Background and Overview
7. Pulmonary Sarcoidosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Pulmonary Sarcoidosis
9. Pulmonary Sarcoidosis Current Treatment and Medical Practices
10. Pulmonary Sarcoidosis Unmet Needs
11. Pulmonary Sarcoidosis Emerging Therapies
12. Pulmonary Sarcoidosis Market Outlook
13. Country-Wise Pulmonary Sarcoidosis Market Analysis (2019–2032)
14. Pulmonary Sarcoidosis Market Access and Reimbursement of Therapies
15. Pulmonary Sarcoidosis Market Drivers
16. Pulmonary Sarcoidosis Market Barriers
17. Pulmonary Sarcoidosis Appendix
18. Pulmonary Sarcoidosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
